Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer

TUESDAY, Sept. 15, 2020 -- For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue of the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news